Compare ResMed Inc. (RMD) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Workday Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Workday Inc trades at $186.52 (market cap $44.89B). The key difference: Workday Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.19% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| RMD | WDAY | |
|---|---|---|
Market Cap | $31.89B | $44.89B |
Sector | Health | Technology |
52-Week High | $283.28 | $247.69 |
52-Week Low | $182.82 | $112.55 |
Enterprise Value | $31.24B | $45.26B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Workday (WDAY) trades at $186.28, down 4.86% on the day, but maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $2.75, beating estimates of $2.61, marking the third consecutive quarterly beat. Revenue growth remains robust, projected to reach $10.2B in 2026, while net income margin improved to 12.32%. Recent news highlights AI adoption gains and a leadership position in cloud HCM suites.
The outlook is positive with analyst consensus favoring a Buy rating and a $204.52 price target, implying potential upside. Key opportunities include AI-driven subscription growth and expanding margins, but risks involve high valuation multiples and competitive pressures in the enterprise software space. Execution on AI initiatives and sustained profitability are critical for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
